Great West Life Assurance Co. Can maintained its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,139 shares of the biopharmaceutical company’s stock at the end of the 2nd quarter. Great West Life Assurance Co. Can’s holdings in Ultragenyx Pharmaceutical were worth $257,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Pacer Advisors Inc. grew its holdings in Ultragenyx Pharmaceutical by 22.6% during the 1st quarter. Pacer Advisors Inc. now owns 3,037 shares of the biopharmaceutical company’s stock worth $206,000 after acquiring an additional 560 shares during the last quarter. Strs Ohio grew its holdings in Ultragenyx Pharmaceutical by 10.7% during the 1st quarter. Strs Ohio now owns 3,100 shares of the biopharmaceutical company’s stock worth $210,000 after acquiring an additional 300 shares during the last quarter. Ameritas Investment Partners Inc. grew its holdings in Ultragenyx Pharmaceutical by 3.7% during the 1st quarter. Ameritas Investment Partners Inc. now owns 3,226 shares of the biopharmaceutical company’s stock worth $219,000 after acquiring an additional 115 shares during the last quarter. Aperio Group LLC grew its holdings in Ultragenyx Pharmaceutical by 8.4% during the 2nd quarter. Aperio Group LLC now owns 3,851 shares of the biopharmaceutical company’s stock worth $239,000 after acquiring an additional 299 shares during the last quarter. Finally, Karp Capital Management Corp bought a new stake in Ultragenyx Pharmaceutical during the 1st quarter worth about $241,000. 96.18% of the stock is currently owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Inc. (NASDAQ RARE) opened at 49.79 on Thursday. The company’s 50-day moving average is $58.78 and its 200 day moving average is $64.17. The company’s market cap is $2.11 billion. Ultragenyx Pharmaceutical Inc. has a 1-year low of $49.56 and a 1-year high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($1.72) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.73) by $0.01. During the same period last year, the company posted ($1.46) earnings per share. On average, equities analysts predict that Ultragenyx Pharmaceutical Inc. will post ($7.21) EPS for the current fiscal year.

RARE has been the topic of a number of research analyst reports. Zacks Investment Research lowered shares of Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $111.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, June 30th. Cowen and Company reaffirmed an “outperform” rating on shares of Ultragenyx Pharmaceutical in a research note on Thursday, June 29th. ValuEngine raised shares of Ultragenyx Pharmaceutical from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Finally, BidaskClub raised shares of Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Tuesday, July 25th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating and eight have given a buy rating to the stock. Ultragenyx Pharmaceutical presently has a consensus rating of “Hold” and a consensus price target of $74.00.

ILLEGAL ACTIVITY WARNING: This article was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/09/14/ultragenyx-pharmaceutical-inc-rare-holdings-held-by-great-west-life-assurance-co-can.html.

In other news, CEO Emil D. Kakkis acquired 7,500 shares of the stock in a transaction dated Monday, August 28th. The stock was bought at an average price of $52.52 per share, with a total value of $393,900.00. Following the completion of the purchase, the chief executive officer now directly owns 430,569 shares of the company’s stock, valued at approximately $22,613,483.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 9.20% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE).

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Stock Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.